# A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)

> **NCT04994522** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 14 (actual)

## Conditions studied

- End Stage Renal Disease
- Renal Impairment

## Interventions

- **DRUG:** Belzutifan

## Key facts

- **NCT ID:** NCT04994522
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-12
- **Primary completion:** 2024-04-01
- **Final completion:** 2024-04-11
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04994522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04994522, "A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04994522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*